 Home > Medical News > Latest Medical News > Novartis' Cananumumab's Phase III study for the treatment of NSCLC failed again

Novartis' Cananumumab's Phase III study for the treatment of NSCLC failed again

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

phase 4 clinical trial

anti cancer mushroom

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Sunshine

Novartis announced on October 25 that the Phase III clinical study (CANOPY-1) of IL-1β inhibitor Canakinumab (canakinumab, ACZ885) combined with pembrolizumab plus platinum dual-drug chemotherapy (CANOPY-1) did not improve overall survival The primary endpoints of OS and PFS.

However, the results showed that based on the subgroup defined by the baseline inflammation biomarker hs-CRP and other biomarkers, PFS and OS had potentially clinically significant improvements in the pre-specified patient subgroups

CANOPY-1 is the second phase III clinical failure of cananumumab in NSCLC indications

Lung cancer is one of the most common cancers in the world, with more than 2 million newly diagnosed cases each year, mainly including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)

Kananuzumab is a human monoclonal antibody that binds to human interleukin-1β (IL-1β) with high affinity and selectively, and neutralizes the activity of IL-1β by blocking its interaction with the receptor

In the Phase III CANTOS trial for cardiovascular disease, Novartis found that lung cancer mortality was significantly reduced as the dose of cananumumab increased

Note: The original text has been deleted

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.